Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101, compared to placebo, in patients with semantic variant primary progressive aphasia (svPPA), a subtype of frontotemporal dementia (FTD)
Phase:
PHASE2
Details
Lead Sponsor:
Hee-Jin Kim
Collaborators:
Asan Medical Center Gangnam Severance Hospital Konkuk University Medical Center